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Background: Septimeb is a new herbal-derived remedy, recently approved for its potential immunomodulatory
effects. Regarding the key role of immune system in the pathogenesis of severe sepsis and lack of any standard
treatment for improving survival of these patients; we evaluated the effect of Septimeb -as an adjutant to standard
treatment-on inflammatory biomarkers and mortality rates in patients with severe sepsis.
Methods: In this multicenter, randomized, single-blind trial, we assigned patients with severe sepsis and Acute
Physiology and Chronic Health Evaluation (APACHE II) score of more than 20 to receive standard treatment of
severe sepsis (control group) or standard treatment plus Septimeb. This group was treated with Septimeb for 14
days then followed up for another14 days. APACHE score, Sequential Organ Failure Assessment (SOFA) and
Simplified Acute Physiology Score (SAPS) were calculated daily. Blood samples were analyzed for interleukin 2
tumor necrosis factor-α, total antioxidant power, platelet growth factor and matrix metalloproteinase 2.
Results: A total of 29 patients underwent randomization (13 in control group and 16 in Septimeb group). There
was significant difference between the Septimeb and control group in the 14 days mortality rate (18.8% vs. 53.85
respectively, P=0.048). Compared to control group, Septimeb was significantly effective in improving SAPS
(P= 0.029), SOFA (P=0.003) and APACHE II (P=0.008) scores. Inflammatory biomarkers didn’t change significantly
between the two groups (P>0.05).
Conclusion: Septimeb reduces mortality rates among patients with severe sepsis and it could be added as a safe
adjutant to standard treatment of sepsis.
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Sepsis is one of the most prevalent and fatal diseases in
Intensive Care Units (ICU) resulted in 30-60% mortality
[1,2]. Sepsis is a systemic inflammatory response to an
infection leading to endothelial dysfunction, impairment
of microcirculation, tissue hypoxia, apoptosis and finally
multiple organ failure and death [3]. Nowadays the role
of inflammatory cytokines, oxidative stress and immune
system in the pathogenesis of sepsis is obvious. Continu-
ous elevated levels of various cytokines in severe sepsis* Correspondence: mojtahed@tums.ac.ir
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reproduction in any medium, provided the orcould result in uncontrolled inflammation [4-7]. Break-
ing of inflammatory cascade may lead to improving of
survival [8]. A significant association exists between in-
flammatory cytokine levels in the first 72 hours of severe
sepsis and severity of tissue hypoxia, organ dysfunction
and mortality [9]. IL-6 and Acute Physiology and
Chronic Health Evaluation (APACHE) II score are used
respectively in prediction of mortality and clinical evalu-
ation of severe septic patients [10]. Therefore modula-
tion of inflammation and immune system response
could be one of the strategic plans to manage sepsis.
Several immunomodulatory therapies have been evalu-
ated in sepsis. Corticosteroids [11,12], anti Tumor Necrosis
Factor α (TNF α) antibodies [13,14], Anti Interleukin 1
antibodies [15], Platelet Aggregating Factor (PAF)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and baseline characteristic of
patients
Control group (N:14) Septimeb group (N:16) P value
Age (year) 45.69 ± 20.67 39.56 ± 16.46 0.38
Male, No. 10 15 0.18
APACHE II 24.76 ± 4.14 27.56 ± 7.39 0.23
SOFA 8.92 ± 1.97 9.25 ± 2.32 0.69
SAPS 47.69 ± 11.61 43.68 ± 11.21 0.35
Data are mean ± SD. APACHE: Acute Physiologic And Chronic Health
Evaluation. SAPS: Simplified Acute Physiologic Score. SOFA: Sequential Organ
Failure Assessment.
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modulation of nutrition [20], modulation of coagulation
[21] and complement pathway [22] are examples of im-
munotherapy in sepsis, but none of them were effective on
survival of patients. Procedures such as plasmapheresis
and hemofiltration slightly improve prognosis of sepsis by
reducing circulating levels of inflammatory cytokines but
couldn’t decrease mortality rate [23].
Analysis of current immunomodulating strategies indi-
cates that monovalent approaches in isolation are
unlikely to restore immunostasis or attain status of
complete therapy. It is likely that multiple immunomo-
dulating strategies will be necessary to achieve clinical
success owing to complex interplay between pathways.
Botanical extracts provide cytoprotective, antiinflamma-
tory, and antimicrobial activities in addition to immu-
noregulatory activity [24].
Septimeb (a more potent form of IMODTM) is a herbal
extracts including Tanacetum vulgare (tansy), Rosa
canina and Urtica dioica (nettle) in addition to selenium,
flavonoids and carotenes. Tanacetum vulgare may relieve
anti-inflammatory symptoms and Rosa canina defers
blood glucose and cholesterol elevation. Extracts from
Urtica dioica may prevent maturation of myeloid den-
dritic cells and reduce T cell responses [25]. Septimeb
can regulate TNF-α, interferon-γ (IFN-γ) and IL-2 [26].
IMOD has been patented in Europe with code of WO/
2007/087825 for its immunomodulator and anti-TNF-α
capacities and improving CD4 in HIV positive patients
[27,28]. The pre-clinical safety studies of IMOD in ani-
mals and phases I and II trials have been successfully
conducted, showing optimistic results [29,30]. As sepsis
is an immune mediated disease and modulating of im-
mune system might be effective in improving prognosis
and survival, we aim to evaluate Septimeb’s effect on
plasma levels of inflammatory biomarkers, and mortality
rates of patients with severe sepsis.
Methods
Patient selection
In all cases, informed consents were received from
patients or their legal guardian. The study procedure
and protocol were approved by the ethical committee of
Tehran University of Medical Sciences (TUMS). Our
clinical trial was registered in Australian Newzeland
Clinical Trial Organization with code number of
(ACTRN012607000376448).
Study subjects
Between March 2009 and April 2011, 29 patients with
severe sepsis and Acute Physiology and Chronic Health
Evaluation (APACHE) scores of more than 20, admitted
to general ICU of “Sina” Hospital of TUMS and
“Shohada” Hospital of Tabriz University of MedicalSciences were enrolled in this study. Exclusion criteria
for all patients were ages below 18 and more than 65
years, pregnancy, breast feeding, over 24 hours of sepsis
diagnosis and death probability within 28 days due to
nonspecific reasons (such as renal or liver failure).
Patients were randomized via block randomization to
receive one of the following treatments: standard treat-
ment for severe sepsis (control group) and standard
treatment plus Septimeb (intervention group) for 14
days and were also followed up for another 14 days.
According to latest international guidelines [31], stand-
ard treatments for severe sepsis were implemented as
following: early resuscitation within the first 6 hours of
admission, appropriate diagnosis studies to ascertain
causative organisms before starting antibiotics, early
administration of broad spectrum antibiotic therapy,
hypotension control with avasopressor, fluid administra-
tion to target Central Venous Pressure (CVP) of 8–12
mmHg and central venous oxygen saturation (Sa O2) >
95%, low dose steroid, glycemic control(blood glucose
<150 mg/dl), target hemoglobin values of 7–9 g/dl in ab-
sence of coronary artery disease or acute hemorrhage,
lung protection ventilation and standard prophylactic
measures for deep vein thrombosis (DVT) and Stress-
related Mucosal Damage (SRMD).
Patients in intervention group received 240mg (4 ml)
of Septimeb in 150 ml of DW 5%, infused over 1.5 hours
on the first day. All hemodynamic data were monitored
during the infusion and in case of any negative
hemodynamic deterioration, dermal rash, urticaria or
anaphylactic reaction, the infusion discontinued. Then
360mg (6 ml) of the drug was infused in 150 ml of
DW5%, everyday for 14 days. The time gap between the
beginnings of treatment with intervention and the diag-
nosis of sepsis was also noted to evaluate possible im-
pact of the onset of intervention on mortality.
Demographic data and clinical information were
obtained at the beginning (Table 1). APACHE scores, se-
quential organ failure assessment (SOFA), and simplified
acute physiology score (SAPS) were calculated daily.
Higher scores indicate more severe illness and a higher
number of therapeutic interventions.
Figure 1 Changes of patients APACHE II score in different days
of study. Difference between two groups is not significant
(P= 0.266). A: APACHE (Acute Physiologic And Chronic Health
Evaluation) 1–14: day 1–14.
Figure 2 Changes of patients SOFA score in different days of
study. Difference between two groups is not significant (P= 0.335).
SO: SOFA (Sequential Organ Failure Assessment) 1–14: day 1–14.
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days were recorded. The standard treatment of sepsis
was continued throughout ICU stay of patients.
Sample collection and handling
All patients had central venous catheters and arterial
lines for blood sampling. For all patients there were
seven scheduled time points to assess IL-2, TNF-α, total
antioxidant power (TAP), Matrix Metalloproteinase2
(MMP2) and Platelet Growth Factor (PGF). The levels
were analyzed via commercially available enzyme-linked
immunosorbent assay kit (BenderMed system, Vienna,
Austria). The first sample was taken on ICU admission
and prior to initiation of the therapy. Other samples
were obtained on days of 1, 2, 3, 7, 10, and 14 post ther-
apies. Blood samples were collected into vacutainer
tubes containing EDTA.
The samples were spun at 3000 × g for 15 minutes in
order to remove cells and cellular debris. The cell free
supernatant and plasma were stored at −80°C until the
time of analysis.
Statistical analysis
All data were expressed as mean ± SD. Univariate com-
parisons of baseline characteristics were performed by
the independent student’s t-test for parametric data and
Mann-Whitney’s t-test for non-parametric data. To
assess differences between the time points in each treat-
ment group, repeated-measure analysis of variance was
done to analyze changes in levels of the biomarkers.
Pearson’s chi square and Kaplan-meier (Log rank) tests
analyzed the differences of survival rates among the two
groups. P-values less than 0.05 were considered statisti-
cally significant.
Result
Thirty patients with severe sepsis and APACHE scores
of over 20 were enrolled in this study (13 patients in
control group and 16 in intervention group). Demo-
graphic and baseline values for APACHE, SOFA and
SAPS scores have been summarized in Table 1. The dif-
ferences in age and sex were not significant between two
groups (P= 0.38 and 0.18, respectively). Differences in
baseline values for APACHE, SOFA and SAPS scores
were not statistically significant either (Table 1).
Compared to controls, Septimeb was effective in im-
proving APACHE (P= 0.229), SOFA (P=0.335) and SAPS
(P= 0.059) scores in 14 days but the trend was not statis-
tically significant (Figures 1, 2 and 3). But the score dif-
ferences between the 14th and first day by LOCF
method (Last Observation Carried Forward), showed
that adding Septimeb was significantly more effective
than standard treatment (Table 2).The mean survival time was 9.84 (7.32-12.36, CI: 95%)
days in control group and 12.93 (11.49-14.3, CI: 95%)
days in Septimeb group. The difference in survival time
was significant (P=0.019) (Figure 4). In the intervention
group, the mortality rate was 18.8% during 28 days while
it was 53.8% in control group, the difference was statisti-
cally significant (P=0.048).
The changes in the levels of biomarkers including IL-2
(P= 0.35), TNF- α (P= 0.66), TAP (P= 0.92), MMP 2 (P=
0.62) and PGF (P= 0.45) were not different among two
groups (Figures 5, 6, 7, 8 and 9). None of the time points
(0,1, 2, 3, 7,10 and 14 days) showed significant differ-
ences between two groups (p>0.05).
Discussion
The results of this study show that Septimeb, as an adju-
tant to standard treatment of severe sepsis could reduce
mortality rates in patients, but has not significant anti-
inflammatory effects.
Figure 3 Changes of patients SAPS score in different days of
study. Difference between two groups is not significant (P= 0.059).
SA: SAPS (Simplified Acute Physiologic Score) 1–14: day 1–14.
Figure 4 Changes of patient’s survival during study period. The
differences in survival time was significant (P=0.019).
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pathophysiology of sepsis and development of novel
therapeutic approaches, mortality of sepsis remains
unacceptably high [32]. As mentioned earlier, immune
system and inflammatory cytokines have a key role in
pathogenesis of sepsis and several studies evaluated the
effect of different immunomodulatory treatment on
severe sepsis, but fail to improve survival of patients
[11-19,21-23,33]. Among immunomodulatory agents,
the activated protein C and corticosteroids are the only
approved treatment for sepsis. According to the results
of PROWESS trial [34,35] and a Meta-analysis [36]
about the ineffectiveness of activated protein C on survival
of patients with sepsis, Food and Drug Administration
(FDA) withdrew this drug from the market and therefore
currently there is no specific treatment for severe sepsis.
Previous studies have shown that monovalent therap-
ies could not restore immunostasis in severe sepsis, so
the need of drugs with polyvalent activities such as bo-
tanical immune-drugs seems inevitable [24,37]. Botanical
immunodrugs e.g. Chinese remedy and green tea have
been found to have dose-dependent attenuate bacterial
endotoxin-induced HMGBI release [38,39]. Septimeb is
a new herbal-derived remedy that has been suggested to
be able to stimulate lymphocytes in order to produce
cytokines in HIV positive patients and also inhibit TNF
alpha and increase interferon gamma and Interleukin 2
[40,41]. The phase I and II trial studies with IMODTM
shows this drug is safe and has no mutagenic or allergenic
potentials. Based on the results of this study, SeptimebTable 2 Change in patient's APACHE, SAPS and SOFA score fr
Contro
APACHE mean difference between 14th and first day±SD −
SOFA mean difference between 14th and first day −
SAPS mean difference between 14th and first day(a more potent form of IMOD) reduced APACHE, SOFA
and SAPS scores, as quantitative indices of clinical status
[29,30]. Improvements of these scores by Septimeb con-
firm the potential of this drug in alleviation of the severity
of sepsis and consequently reduced mortality rates of
patients.
The results of previous study [30] did not show any
improvement in survival of septic patients, but in the
current study Septimeb decreased mortality rate signifi-
cantly, this could be because of larger sample size in this
study.
Immunotherapy must be applied early during the de-
velopment of immune-dysfunction following trauma or
acute onset of infection, to ensure that all cellular com-
ponents of immune system will be protected. There is a
much earlier temporal relationship between inflamma-
tion and the onset of organ dysfunction. Mean bio-
marker levels during 72 hours were significantly greater
in hospital non-survivors [42]. Supporting evidence
showed that the initial inflammatory response directly
correlates to early, but not late sepsis mortality [8].
A complex interaction of cytokines and cytokine-
neutralizing molecules probably determines the clinical
presentation and course of sepsis. Intervening in this
sequence of events to modify the host inflammatory
responses may be a beneficial treatment strategy for sep-
sis, but currently tested anticytokine therapies have beenom 1st day to 14th day study




Figure 5 Changes in blood TNF-α level in different days of
study. Data are mean ± SE. **Difference between two groups is not
significant at P>0.05. Figure 7 Changes in blood PGF levels in different days of
study. Data are mean ± SE. **Difference between two groups is not
significant at P>0.05.
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markers didn’t change significantly by Septimeb and
positive effect of Septimeb on mortality rate might be
due to other mechanisms. The main problems in severe
sepsis are O2 extraction and O2 consumption. The crit-
ical importance of tissue oxygenation was addressed by a
study in which patients in the earliest stages of sepsis
were treated by aggressive management with fluids,
blood transfusion and inotropic agents to optimize
hemodynamic function [43]. After macrocirculatory
resuscitation, many patients still demonstrate multisys-
tem organ dysfunction and shock. The recent landscapeFigure 6 Changes in blood IL-2 level in different days of study.
Data are mean ± SE. **Difference between two groups is not
significant at P>0.05.of sepsis research is focusing on two separate mechan-
isms that may explain the persistence of the shock state.
The first is the role of the microcirculation in the body,
and the mixed response of various circulatory beds to
the sepsis. The second is that the cells and mitochondria
receiving adequate perfusion and oxygenation may still
have a decreased ability to properly utilize energy to form
ATP, referred to as cytopathic hypoxia [44], that can lead
to profound metabolic alterations and the inability to sup-
ply energy to the tissues. These two represent attractiveFigure 8 Changes in blood MMP-2 level in different days of
study. Data are mean ± SE. **Difference between two groups is not
significant at P>0.05.
Figure 9 Changes in blood TAP level in different days of study.
Data are mean ± SE. **Difference between two groups is not
significant at P>0.05.
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treatment of septic shock. Therefore improving tissue
oxygenation could be a possible mechanism of Septimeb
in reduction of sepsis mortality.
Fortunately, Septimeb showed no adverse effects on
coagulation factors like platelet count, prothrombin
time, partial thromboplastin time, fibrinogen, and D-
dimer. Hemodynamic instability and anaphylactic reac-
tions were not observed during infusion. It could be a
safe adjutant to other standard treatments of sepsis [45].
Conclusion
Despite several limitations of this study, especially the
small sample size, Septimeb shows positive effects on sur-
vival of patients with severe sepsis, considering the with-
drawal of activated protein C from markets. Additional
studies with adequate sample size is recommended to be
performed with Septimeb, but regarding the results and
also limited side effects of Septimeb, it could be consid-
ered as an adjutant along with other standard measures
for treatment of severe sepsis.
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